(GLPG) Galapagos - Ratings and Ratios
CAR-T, Oncology, Immunology, Pipeline, Trials
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 29.7% |
| Value at Risk 5%th | 43.6% |
| Relative Tail Risk | -10.74% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.25 |
| Alpha | 35.38 |
| CAGR/Max DD | -0.16 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.428 |
| Beta | 0.393 |
| Beta Downside | 0.195 |
| Drawdowns 3y | |
|---|---|
| Max DD | 49.03% |
| Mean DD | 26.71% |
| Median DD | 28.17% |
Description: GLPG Galapagos January 13, 2026
Galapagos NV (NASDAQ:GLPG) is a Belgium-based biotech focused on developing small-molecule and cell-based therapies for oncology and immunology, primarily targeting the U.S. and European markets. The firm was founded in 1999 and trades as a common stock under the ticker GLPG.
The current pipeline centers on four CAR-T candidates manufactured at the point-of-care: GLPG3667 (completed Phase 1b), GLPG5101 (CD19 CAR-T for relapsed/refractory non-Hodgkin lymphoma, Phase 1/2), GLPG5201 (CD19 CAR-T for relapsed/refractory chronic lymphocytic leukemia, Phase 1/2), and GLPG5301 (BCMA CAR-T for relapsed/refractory multiple myeloma, Phase 1/2). All trials are early-stage, so efficacy and safety outcomes remain highly uncertain.
Galapagos maintains strategic collaborations with Gilead Sciences and AbbVie, which together have generated roughly $250 million in upfront payments and milestone potential (based on the most recent public filings). As of the latest 10-Q, the company reported a cash and cash-equivalents balance of about $800 million, giving it a runway of roughly 18-24 months at current burn rates. The broader CAR-T sector is experiencing rapid growth, with market analysts projecting a compound annual growth rate of ~30 % through 2030, driven by expanding indications and point-of-care manufacturing models.
Given the early-stage nature of Galapagos’ candidates and the competitive landscape, investors should closely monitor trial read-outs, partnership milestone triggers, and cash-flow dynamics before forming a valuation view. For a deeper quantitative assessment, see the ValueRay analysis of GLPG.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -436.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA 1.42 > 1.0 |
| NWC/Revenue: 1145 % < 20% (prev 1338 %; Δ -193.5% < -1%) |
| CFO/TA -0.07 > 3% & CFO -269.4m > Net Income -436.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 8.63 > 1.5 & < 3 |
| Outstanding Shares: last quarter (65.9m) vs 12m ago -0.08% < -2% |
| Gross Margin: -38.90% > 18% (prev 0.57%; Δ -3947 % > 0.5%) |
| Asset Turnover: 6.91% > 50% (prev 5.75%; Δ 1.17% > 0%) |
| Interest Coverage Ratio: -10.69 > 6 (EBITDA TTM -503.2m / Interest Expense TTM 24.4m) |
Altman Z'' 3.98
| A: 0.80 (Total Current Assets 3.72b - Total Current Liabilities 430.7m) / Total Assets 4.13b |
| B: -0.16 (Retained Earnings -678.8m / Total Assets 4.13b) |
| C: -0.06 (EBIT TTM -260.7m / Avg Total Assets 4.15b) |
| D: -0.27 (Book Value of Equity -340.8m / Total Liabilities 1.25b) |
| Altman-Z'' Score: 3.98 = AA |
Beneish M -3.26
| DSRI: 0.87 (Receivables 91.3m/87.2m, Revenue 286.9m/239.7m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.60 (AQ_t 0.07 / AQ_t-1 0.12) |
| SGI: 1.20 (Revenue 286.9m / 239.7m) |
| TATA: -0.04 (NI -436.0m - CFO -269.4m) / TA 4.13b) |
| Beneish M-Score: -3.26 = AA |
ValueRay F-Score (Strict, 0-100) 35.71
| 1. Piotroski: 0.50pt |
| 2. FCF Yield: 17.02% |
| 3. FCF Margin: data missing |
| 4. Debt/Equity: 0.00 |
| 5. Debt/Ebitda: data missing |
| 6. ROIC - WACC: -15.00% |
| 7. RoE: -15.62% |
| 8. Revenue Trend: -12.41% |
| 9. EPS Trend: -27.22% |
What is the price of GLPG shares?
Over the past week, the price has changed by +2.63%, over one month by +4.43%, over three months by +7.40% and over the past year by +44.90%.
Is GLPG a buy, sell or hold?
- Strong Buy: 0
- Buy: 0
- Hold: 4
- Sell: 1
- Strong Sell: 1
What are the forecasts/targets for the GLPG price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 27.4 | -20.5% |
| Analysts Target Price | 27.4 | -20.5% |
| ValueRay Target Price | 37 | 7.4% |
GLPG Fundamental Data Overview January 18, 2026
P/E Forward = 344.8276
P/S = 7.6985
P/B = 0.7776
Revenue TTM = 286.9m EUR
EBIT TTM = -260.7m EUR
EBITDA TTM = -503.2m EUR
Long Term Debt = 7.50m EUR (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.04m EUR (from shortTermDebt, last quarter)
Debt = 8.81m EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = -66.9m EUR (from netDebt column, last quarter)
Enterprise Value = -1.69b EUR (1.89b + Debt 8.81m - CCE 3.58b)
Interest Coverage Ratio = -10.69 (Ebit TTM -260.7m / Interest Expense TTM 24.4m)
EV/FCF = 5.87x (Enterprise Value -1.69b / FCF TTM -287.0m)
FCF Yield = 17.02% (FCF TTM -287.0m / Enterprise Value -1.69b)
FCF Margin = -100.0% (FCF TTM -287.0m / Revenue TTM 286.9m)
Net Margin = -151.9% (Net Income TTM -436.0m / Revenue TTM 286.9m)
Gross Margin = -38.90% ((Revenue TTM 286.9m - Cost of Revenue TTM 398.5m) / Revenue TTM)
Gross Margin QoQ = none% (prev 92.79%)
Tobins Q-Ratio = -0.41 (set to none) (Enterprise Value -1.69b / Total Assets 4.13b)
Interest Expense / Debt = 266.8% (Interest Expense 23.5m / Debt 8.81m)
Taxrate = 21.0% (US default 21%)
NOPAT = -206.0m (EBIT -260.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.63 (Total Current Assets 3.72b / Total Current Liabilities 430.7m)
Debt / Equity = 0.00 (Debt 8.81m / totalStockholderEquity, last quarter 2.88b)
Debt / EBITDA = 0.13 (negative EBITDA) (Net Debt -66.9m / EBITDA -503.2m)
Debt / FCF = 0.23 (negative FCF - burning cash) (Net Debt -66.9m / FCF TTM -287.0m)
Total Stockholder Equity = 2.79b (last 4 quarters mean from totalStockholderEquity)
RoA = -10.51% (Net Income -436.0m / Total Assets 4.13b)
RoE = -15.62% (Net Income TTM -436.0m / Total Stockholder Equity 2.79b)
RoCE = -9.32% (EBIT -260.7m / Capital Employed (Equity 2.79b + L.T.Debt 7.50m))
RoIC = -7.67% (negative operating profit) (NOPAT -206.0m / Invested Capital 2.68b)
WACC = 7.33% (E(1.89b)/V(1.90b) * Re(7.36%) + (debt cost/tax rate unavailable))
Discount Rate = 7.36% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 0.0 | Cagr: 0.0%
Fair Price DCF = unknown (Cash Flow -287.0m)
EPS Correlation: -27.22 | EPS CAGR: 1.55% | SUE: 0.09 | # QB: 0
Revenue Correlation: -12.41 | Revenue CAGR: -20.34% | SUE: 0.02 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.08 | Chg30d=+0.445 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=0.27 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+108.9% | Growth Revenue=-3.2%
Additional Sources for GLPG Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle